Elsevier

Autoimmunity Reviews

Volume 9, Issue 10, August 2010, Pages 701-707
Autoimmunity Reviews

Review
How early is the atherosclerotic risk in rheumatoid arthritis?

https://doi.org/10.1016/j.autrev.2010.06.001Get rights and content

Abstract

Rheumatoid arthritis is a systemic disease characterized by a reduced life expectancy mainly due to cardiovascular disease. In long-standing disease, it has been widely demonstrated that both traditional cardiovascular risk factors than chronic inflammation and immune-mediated mechanisms play a relevant role in atherosclerosis. Recently, it has been shown that the increased cardiovascular risk appears to precede rheumatoid arthritis onset and that particular immune and inflammatory factors, predating disease presentation, in association with a well-defined genetic background, may be associated with increased risk of accelerated atherosclerosis in patients with early disease. However, the effect of early immunosuppressive treatment on cardiovascular disease outcome remains uncertain. A multidisciplinary cardiovascular risk management is required to provide the better care of patients with RA at disease onset.

Introduction

Rheumatoid arthritis (RA) is a prototypical chronic systemic inflammatory disease that can be reasonably considered an independent cardiovascular disease (CVD) risk factor, as well as diabetes mellitus (DM). Indeed, both cross-sectional and prospective studies demonstrated that incidence and prevalence of CVD in RA are increased to a degree comparable with that in type 2 DM and that this largely results from preclinical arterial wall atherosclerotic damage [1], [2], [3]. Of consequence, mortality rate for CVD, in particular for ischemic heart disease (IHD), is higher in RA patients than in the general population with an overall standardized mortality ratio ranging from 1.5 to 5.0 [4]. Both traditional risk factors than inflammatory and immune-mediated mechanisms are now recognized to act synergistically in determining the increased risk of subclinical atherosclerosis (ATS) and consequent CV events in RA [5]. In fact, an intriguing parallelism between immune-mediate mechanisms underlying RA synovial inflammation and ATS vascular damage has been well established [5].

The excess of CV mortality risk, however, has been widely recognized in patients with established long-lasting disease. Nevertheless, the relevance of prompt RA diagnosis and rapid suppression of inflammation in patients presenting with recent onset inflammatory polyarthritis has been emphasized in recent years [6]. Several reasons justify the importance of prompt disease diagnosis and treatment in an early phase from symptom onset, generally within 1 year. In fact, there is some evidence that the excess of CVD risk, mainly for IHD, seems to precede the ACR criteria-based diagnosis of RA and to begin early in the disease course, being apparent within the first 5 years after symptoms onset [7]. Moreover, it appears to be higher in young (< 55 years old) seropositive patients and independent of increased incidence of traditional risk factors [8], [9]. Male sex, higher age at diagnosis, disability, rheumatoid factor (RF) and comorbidity have been described as significant predictors of mortality at 10 years in a cohort of early RA [10]. The relevance of such findings is further strengthened by the observation that inflammatory and immune-mediated processes characterizing disease pathogenesis may predate clinical disease presentation or may be detected at the time of diagnosis [11]. Thus, considering the pivotal role played by inflammatory and disease-related immunologic factors in inducing subclinical ATS in RA [5], [12], [13], it is intriguing to postulate that exposure to these factors before disease clinical presentation may trigger and accelerate the atherosclerotic process in subjects at increased risk of RA development [14].

Purpose of the present review is to analyze the possible pathogenic links between traditional and disease-related CV risk factors characterizing disease before clinical manifestation onset and precocious atherosclerotic damage in patients with early RA.

Section snippets

Genetic factors

Genetic background has been recently recognized as an important factor in determining disease development and persistence, accounting for up to 50%–60% of disease susceptibility. The strongest genetic susceptibility effects are conferred by the HLA-DRB1 locus on chromosome 6 and by the protein tyrosine phosphatase 22 (PTPN22) gene on chromosome 1p13. Moreover, it is now recognized that particular genes, interacting with certain environmental factors such as smoking, play an important role in

Subclinical atherosclerosis

Endothelial dysfunction and high-resolution ultrasonographic measurement of carotid IMT are well established surrogate markers of subclinical ATS in RA able to identify two different stages of pathogenic mechanisms leading to atherosclerotic damage. Endothelial dysfunction, indeed, is considered the earliest, but reversible, stage of atherogenesis and multiple elements, including hemodynamic, traditional and inflammatory factors, have been associated with impaired endothelial function in RA [59]

Treatment

In RA, beneficial and cardioprotective effects of conventional disease-modifying anti-rheumatic drugs (DMARDs) and biologic agents have been reported for a number of CV risk conditions, including lipid profile, metabolic syndrome and surrogate measures of subclinical ATS, in particular in patients responding to anti-rheumatic therapy [69], [70], [71]. Treatment duration is an important factor which must be considered when the effect of anti-inflammatory therapy on vascular function is

Conclusion

In summary, recent evidence seems to suggest that in subjects with RA accelerated ATS may occur early in disease process and a pathogenic model could be hypothesized (Fig. 1). Genetic background has been demonstrated to be a relevant pathogenic factor not only in disease susceptibility but also in increasing preclinical atherosclerotic risk in this population. The demonstration that specific CV risk factors and inflammatory and immune-mediated mechanisms associated with atherosclerotic damage

Take-home messages

  • Early RA patients are at increased risk of subclinical ATS just at disease onset.

  • Multiple mechanisms contribute to determine precocious atherosclerotic damage in early RA.

  • Traditional and disease-related ATS risk factors should be identified in the preclinical phase of the disease.

  • Multidisciplinary algorithm for CVD risk management needs to be developed in patients with RA at disease onset.

  • Appropriate CV risk management and rapid pharmacological therapy introduction should be considered,

References (80)

  • D.W. McCarey et al.

    Trail of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial

    Lancet

    (2004)
  • H. John et al.

    Cardiovascular co-morbidity in early rheumatoid arthritis

    Best Pract Res Clin Rheumatol

    (2009)
  • V.P. van Halm et al.

    Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross-sectional study: the CARRE Investigation

    Ann Rheum Dis

    (2009)
  • M.J. Peters et al.

    Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study

    Arthritis Rheum

    (2009)
  • Y. Shoenfeld et al.

    Accelerated atherosclerosis in autoimmune rheumatic diseases

    Circulation

    (2005)
  • I.A. Ku et al.

    Rheumatoid arthritis — a model of systemic inflammation driving atherosclerosis

    Circ J

    (2009)
  • D. van Schaardenburg et al.

    Clinical approaches to early inflammatory arthritis

    Nat Rev Rheumatol

    (2009)
  • A. Young et al.

    Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischemic heart disease and in pulmonary fibrosis

    Rheumatology

    (2007)
  • H. Maradit-Kremers et al.

    Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population based cohort study

    Arthritis Rheum

    (2005)
  • S.M. Naz et al.

    The influence of age at symptoms onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis

    Arthritis Rheum

    (2008)
  • B.J. Radovits et al.

    Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis

    Arthritis Care Res

    (2010)
  • S. Rantapää-Dahlqvist

    What happens before the onset of rheumatoid arthritis?

    Curr Opin Rheumatol

    (2009)
  • F. Montecucco et al.

    Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis

    Rheumatology

    (2009)
  • L.E. Full et al.

    The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus

    Arthritis Res Ther

    (2009)
  • E. Myasoedova et al.

    Cardiovascular disease in rheumatoid arthritis: a step forward

    Curr Opin Rheumatol

    (2010)
  • S.Y. Bang et al.

    Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status

    Arthritis Rheum

    (2010)
  • T.M. Farragher et al.

    Association of HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

    Arthritis Rheum

    (2008)
  • D.L. Mattey et al.

    Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis

    Arthritis Rheum

    (2007)
  • M.A. Gonzales-Gay et al.

    HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis

    Arthritis Rheum

    (2007)
  • M.A. Gonzales-Gay et al.

    Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis

    Clin Exp Rheumatol

    (2009)
  • R. Palomino-Morales et al.

    Interleukin-6 gene-174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis

    Clin Exp Rheumatol

    (2009)
  • J.C. Vallvé et al.

    Tumor necrosis factor-α-1031T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis

    J Rheumatol

    (2008)
  • R. Palomino-Morales et al.

    Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain

    Clin Exp Rheumatol

    (2010)
  • J. van Nies et al.

    TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies

    Arthritis Res Ther

    (2010)
  • R. Gerli et al.

    Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis

    Ann Rheum Dis

    (2008)
  • R. Gerli et al.

    Precocious atherosclerosis in rheumatoid arthritis. Role of traditional and disease-related cardiovascular risk factors

    Ann N Y Acad Sci

    (2007)
  • S. Brady et al.

    The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis

    J Rheumatol

    (2009)
  • S.E. Gabriel

    Heart disease and rheumatoid arthritis: understanding the risks

    Ann Rheum Dis

    (2009)
  • V.P. van Halm et al.

    Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis

    Ann Rheum Dis

    (2007)
  • A.N. Georgiadis et al.

    Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment — a prospective, controlled study

    Arthritis Res Ther

    (2006)
  • Cited by (0)

    View full text